All Stories

  1. Multi-omics analysis-based clinical and functional significance of a novel prognostic and immunotherapeutic gene signature derived from amino acid metabolism pathways in lung adenocarcinoma

    Article • Frontiers in Immunology, December 2024, Frontiers

    Tetsuro Sasada

  2. Enhancing Mass spectrometry-based tumor immunopeptide identification: machine learning filter leveraging HLA binding affinity, aliphatic index and retention time deviation

    Article • Computational and Structural Biotechnology Journal, December 2024, Elsevier

    Tetsuro Sasada

  3. Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy

    Article • Medical Oncology, September 2024, Springer Science + Business Media

    Tetsuro Sasada

  4. Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

    Article • Biomedicines, August 2024, MDPI AG

    Tetsuro Sasada

  5. Recent Trends and Potential of Radiotherapy in the Treatment of Anaplastic Thyroid Cancer

    Article • Biomedicines, June 2024, MDPI AG

    Tetsuro Sasada

  6. MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors

    Article • International Journal of Clinical Oncology, April 2024, Springer Science + Business Media

    Tetsuro Sasada

  7. Characterization of Pre- and Post-treatment Soluble Immune Mediators and the Tumor Microenvironment in NSCLC Patients Receiving PD-1/L1 Inhibitor Monotherapy

    Article • March 2024, Springer Science + Business Media

    Tetsuro Sasada

  8. Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors

    Article • Frontiers in Cell and Developmental Biology, January 2024, Frontiers

    Tetsuro Sasada

  9. Novel chimeric antigen receptor‐expressing T cells targeting the malignant mesothelioma‐specific antigen sialylated HEG1

    Article • International Journal of Cancer, January 2024, Wiley

    Tetsuro Sasada

  10. Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer

    Article • Genes & Immunity, December 2023, Springer Science + Business Media

    Tetsuro Sasada

  11. Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma

    Article • Frontiers in Pharmacology, November 2023, Frontiers

    Tetsuro Sasada

  12. Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer

    Article • Lung Cancer, October 2023, Elsevier

    Tetsuro Sasada

  13. Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors

    Article • Cancer Medicine, September 2023, Wiley

    Tetsuro Sasada

  14. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures

    Article • Journal for ImmunoTherapy of Cancer, July 2023, BMJ

    Tetsuro Sasada

  15. Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors

    Article • Medical Oncology, May 2023, Springer Science + Business Media

    Tetsuro Sasada

  16. PD-L1 expression in anaplastic thyroid carcinoma treated with lenvatinib

    Article • March 2023, Springer Science + Business Media

    Tetsuro Sasada

  17. A phase 1 trial of NY‐ESO‐1‐specific TCR‐engineered T‐cell therapy combined with a lymph node‐targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma

    Article • International Journal of Cancer, February 2023, Wiley

    Tetsuro Sasada

  18. Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors

    Article • January 2023, Research Square

    Tetsuro Sasada

  19. Evaluation of X-ray and carbon-ion beam irradiation with chemotherapy for the treatment of cervical adenocarcinoma cells in 2D and 3D cultures

    Article • Cancer Cell International, December 2022, Springer Science + Business Media

    Tetsuro Sasada

  20. Evaluation of X-ray and carbon-ion beam irradiation with chemotherapy for the treatment of cervical adenocarcinoma cells on 2D and 3D cultures

    Article • October 2022, Research Square

    Tetsuro Sasada

  21. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome

    Article • Journal for ImmunoTherapy of Cancer, June 2022, BMJ

    Tetsuro Sasada

  22. Exhaustion of CAR T cells: potential causes and solutions

    Article • Journal of Translational Medicine, May 2022, Springer Science + Business Media

    Tetsuro Sasada

  23. Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model

    Article • Journal for ImmunoTherapy of Cancer, May 2022, BMJ

    Tetsuro Sasada

  24. Personalized peptide vaccines

    Article • January 2022, Elsevier

    Tetsuro Sasada

  25. Personalized Cancer Vaccines Targeting Neoantigens

    Article • January 2022, Springer Science + Business Media

    Tetsuro Sasada

  26. Possible Role of Cytochrome P450 1B1 in the Mechanism of Gemcitabine Resistance in Pancreatic Cancer

    Article • Biomedicines, October 2021, MDPI AG

    Tetsuro Sasada

  27. Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody

    Article • Medical Oncology, March 2021, Springer Science + Business Media

    Tetsuro Sasada

  28. Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer

    Article • Molecular and Clinical Oncology, December 2020, Spandidos Publications

    Tetsuro Sasada

  29. Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy

    Article • Journal of Immunology Research, November 2020, Wiley

    Tetsuro Sasada

  30. High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer

    Article • International Journal of Oncology, November 2020, Spandidos Publications

    Tetsuro Sasada

  31. C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma

    Article • Cancer Chemotherapy and Pharmacology, June 2020, Springer Science + Business Media

    Tetsuro Sasada

  32. Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma

    Article • Medical Oncology, May 2020, Springer Science + Business Media

    Tetsuro Sasada

  33. High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer

    Article • Oncology Reports, May 2020, Spandidos Publications

    Tetsuro Sasada

  34. Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients

    Article • International Journal of Oncology, March 2020, Spandidos Publications

    Tetsuro Sasada

  35. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial

    Article • Medical Oncology, February 2020, Springer Science + Business Media

    Tetsuro Sasada

  36. High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer

    Article • PLOS One, January 2020, PLOS

    Tetsuro Sasada

  37. Distribution of Regulatory T-Cells and Other Phenotypes of T-Cells in Tumors and Regional Lymph Nodes of Colorectal Cancer Patients

    Article • In Vivo, January 2020, International Institute of Anticancer Research

    Tetsuro Sasada

  38. Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial

    Article • Cancer Science, September 2019, Wiley

    Tetsuro Sasada

  39. Prospects for a personalized peptide vaccine against lung cancer

    Article • Expert Review of Vaccines, June 2019, Taylor & Francis

    Tetsuro Sasada

  40. Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy

    Article • Oncotarget, March 2019, Impact Journals, LLC

    Tetsuro Sasada

  41. Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations

    Article • Cancers, February 2019, MDPI AG

    Tetsuro Sasada

  42. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma

    Article • Neuro-Oncology, November 2018, Oxford University Press (OUP)

    Tetsuro Sasada

  43. Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti‐PD‐1 inhibitor

    Article • International Journal of Cancer, November 2018, Wiley

    Tetsuro Sasada

  44. Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin

    Article • Oncotarget, September 2018, Impact Journals, LLC

    Tetsuro Sasada

  45. Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer

    Article • Oncotarget, July 2018, Impact Journals, LLC

    Tetsuro Sasada

  46. Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment

    Article • Head & Neck, May 2018, Wiley

    Takeharu Ono, Tetsuro Sasada

  47. Use of patient-derived xenograft mouse models in cancer research and treatment

    Article • Future Science OA, March 2018, Future Science

    Tetsuro Sasada

  48. Personalized peptide vaccines for cancer therapy: current progress and state of the art

    Article • Expert Review of Precision Medicine and Drug Development, November 2017, Taylor & Francis

    Tetsuro Sasada

  49. Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer

    Article • Clinical Lung Cancer, November 2017, Elsevier

    Tetsuro Sasada

  50. Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma

    Article • Cancer Science, October 2017, Wiley

    Tetsuro Sasada

  51. Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma

    Article • Oncotarget, October 2017, Impact Journals, LLC

    Tetsuro Sasada

  52. Are peptide vaccines viable in combination with other cancer immunotherapies?

    Article • Future Oncology, August 2017, Future Medicine

    Tetsuro Sasada

  53. Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies

    Article • Cancer Science, July 2017, Wiley

    Tetsuro Sasada

  54. Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial

    Article • Clinical Cancer Research, July 2017, American Association for Cancer Research (AACR)

    Tetsuro Sasada

  55. Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy

    Article • Oncotarget, June 2017, Impact Journals, LLC

    Tetsuro Sasada

  56. A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer

    Article • Cancer Science, May 2017, Wiley

    Tetsuro Sasada

  57. Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11+ or ‐A33+ allele

    Article • Cancer Science, April 2017, Wiley

    Tetsuro Sasada

  58. Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females

    Article • Experimental and Therapeutic Medicine, February 2017, Spandidos Publications

    Tetsuro Sasada

  59. Current Status and Future Prospects of Peptide-Based Cancer vaccines

    Article • Immunotherapy, November 2016, Taylor & Francis

    Tetsuro Sasada

  60. Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment

    Article • Frontiers in Pharmacology, October 2016, Frontiers

    Tetsuro Sasada

  61. Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma

    Article • Clinical Cancer Research, June 2016, American Association for Cancer Research (AACR)

    Tetsuro Sasada

  62. Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients

    Article • Cancer Science, April 2016, Wiley

    Tetsuro Sasada

  63. Personalized immunotherapy in colorectal cancer

    Article • Expert Review of Precision Medicine and Drug Development, April 2016, Taylor & Francis

    Tetsuro Sasada

  64. Prospect and progress of personalized peptide vaccinations for advanced cancers

    Article • Expert Opinion on Biological Therapy, March 2016, Informa Healthcare

    Tetsuro Sasada

  65. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer

    Article • Medical Oncology, January 2016, Springer Science + Business Media

    Tetsuro Sasada

  66. An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy

    Article • Clinical Cancer Research, January 2016, American Association for Cancer Research (AACR)

    Tetsuro Sasada

  67. Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

    Article • Journal of Immunology Research, January 2016, Wiley

    Tetsuro Sasada

  68. Designing a broad-spectrum integrative approach for cancer prevention and treatment

    Article • Seminars in Cancer Biology, December 2015, Elsevier

    Professor Nicol Keith, Dr. H.P. Vasantha Rupasinghe, Colleen Curran, Dr Gunjan Guha, Tetsuro Sasada, Gloria Huang

  69. Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients

    Article • Medical Oncology, October 2015, Springer Science + Business Media

    Tetsuro Sasada

  70. Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A26 allele

    Article • Cancer Science, September 2015, Wiley

    Tetsuro Sasada

  71. Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination

    Article • Human Vaccines & Immunotherapeutics, September 2015, Taylor & Francis

    Tetsuro Sasada

  72. Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression

    Article • Medical Oncology, February 2015, Springer Science + Business Media

    Tetsuro Sasada

  73. Personalized peptide vaccination for advanced colorectal cancer

    Article • OncoImmunology, February 2015, Taylor & Francis

    Tetsuro Sasada

  74. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

    Article • Journal of Immunology Research, January 2015, Wiley

    Tetsuro Sasada

  75. Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

    Article • Cancer Immunology Research, December 2014, American Association for Cancer Research (AACR)

    Tetsuro Sasada

  76. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens

    Article • International Journal of Oncology, October 2014, Spandidos Publications

    Tetsuro Sasada

  77. Human dermal fibroblast migration induced by fibronectin in autocrine and paracrine manners

    Article • Experimental Dermatology, September 2014, Wiley

    Dr Chika Ohata, Tetsuro Sasada

  78. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens

    Article • Immunobiology, August 2014, Elsevier

    Tetsuro Sasada

  79. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

    Article • Breast Cancer Research, July 2014, Springer Science + Business Media

    Tetsuro Sasada

  80. Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

    Article • Cancer Immunology Research, July 2014, American Association for Cancer Research (AACR)

    Tetsuro Sasada

  81. Genetic factors associated with serum haptoglobin level in a Japanese population

    Article • Clinica Chimica Acta, June 2014, Elsevier

    Tetsuro Sasada

  82. Personalized Peptide Vaccine for Treatment of Advanced Cancer

    Article • Current Medicinal Chemistry, May 2014, Bentham Science Publishers

    Tetsuro Sasada

  83. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients

    Article • Immunopharmacology and Immunotoxicology, April 2014, Taylor & Francis

    Tetsuro Sasada

  84. Combinational Delivery of Lipid-Enveloped Polymeric Nanoparticles Carrying Different Peptides for Anti-Tumor Immunotherapy

    Article • Nanomedicine, April 2014, Taylor & Francis

    Tetsuro Sasada

  85. Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib

    Article • PLOS One, January 2014, PLOS

    Tetsuro Sasada

  86. A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

    Article • BMC Cancer, December 2013, Springer Science + Business Media

    Tetsuro Sasada

  87. EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation

    Article • PLOS One, November 2013, PLOS

    Tetsuro Sasada

  88. Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases

    Article • Developmental & Comparative Immunology, September 2013, Elsevier

    Tetsuro Sasada

  89. Identification of human leucocyte antigen (HLA)‐A*0201‐restricted cytotoxic T lymphocyte epitopes derived from HLA‐DOβ as a novel target for multiple myeloma

    Article • British Journal of Haematology, August 2013, Wiley

    Tetsuro Sasada

  90. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients

    Article • Cancer Science, August 2013, Wiley

    Tetsuro Sasada

  91. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells

    Article • Journal of Clinical Investigation, August 2013, American Society for Clinical Investigation

    Tetsuro Sasada

  92. A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients

    Article • Oncology Reports, June 2013, Spandidos Publications

    Tetsuro Sasada

  93. Current status of immunotherapy for the treatment of biliary tract cancer

    Article • Human Vaccines & Immunotherapeutics, May 2013, Taylor & Francis

    Tetsuro Sasada

  94. Haptoglobin Proved a Prognostic Biomarker in Peripheral Blood of Patients with Personalized Peptide Vaccinations for Advanced Castration-Resistant Prostate Cancer

    Article • Bioscience Biotechnology and Biochemistry, April 2013, Taylor & Francis

    Tetsuro Sasada

  95. Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients’ Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine

    Article • Evidence-based Complementary and Alternative Medicine, January 2013, Wiley

    Tetsuro Sasada

  96. Next-generation peptide vaccines for advanced cancer

    Article • Cancer Science, December 2012, Wiley

    Tetsuro Sasada

  97. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy

    Article • European Journal of Radiology, December 2012, Elsevier

    Tetsuro Sasada

  98. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine

    Article • Medical Oncology, November 2012, Springer Science + Business Media

    Tetsuro Sasada

  99. Detecting T-cell reactivity to whole cell vaccines

    Article • OncoImmunology, October 2012, Taylor & Francis

    Tetsuro Sasada

  100. Personalized peptide vaccination: A novel immunotherapeutic approach for advanced cancer

    Article • Human Vaccines & Immunotherapeutics, September 2012, Taylor & Francis

    Tetsuro Sasada

  101. Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides

    Article • Virology Journal, September 2012, Springer Science + Business Media

    Tetsuro Sasada

  102. Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia

    Article • Oncology Letters, June 2012, Spandidos Publications

    Tetsuro Sasada

  103. Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer

    Article • Cancer Science, February 2012, Wiley

    Tetsuro Sasada

  104. Personalized peptide vaccination in patients with refractory non-small cell lung cancer

    Article • International Journal of Oncology, February 2012, Spandidos Publications

    Tetsuro Sasada

  105. Controversies in Clinical Trials of Cancer Vaccines for Glioblastoma

    Article • Journal of Vaccines & Vaccination, January 2012, OMICS Publishing Group

    Tetsuro Sasada

  106. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis

    Article • Experimental and Therapeutic Medicine, December 2011, Spandidos Publications

    Tetsuro Sasada

  107. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination

    Article • Cancer, November 2011, Wiley

    Tetsuro Sasada

  108. Variation of Tumor-Infiltrating Lymphocytes in Human Cancers: Controversy on Clinical Significance

    Article • Immunotherapy, October 2011, Taylor & Francis

    Tetsuro Sasada

  109. Phase II study of personalized peptide vaccination for castration‐resistant prostate cancer patients who failed in docetaxel‐based chemotherapy

    Article • The Prostate, September 2011, Wiley

    Tetsuro Sasada

  110. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery

    Article • Biomaterials, May 2011, Elsevier

    Tetsuro Sasada

  111. Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells

    Article • Medical Oncology, March 2011, Springer Science + Business Media

    Tetsuro Sasada

  112. Diffusion‐weighted Magnetic Resonance Imaging for Detecting Lymph Node Metastasis of Rectal Cancer

    Article • World Journal of Surgery, February 2011, Wiley

    Tetsuro Sasada

  113. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy

    Article • Lung Cancer, January 2011, Elsevier

    Tetsuro Sasada

  114. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination

    Article • Cancer Biology & Therapy, December 2010, Taylor & Francis

    Tetsuro Sasada

  115. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines

    Article • European Journal of Cancer, June 2010, Elsevier

    Tetsuro Sasada

  116. Graft-versus-Leukemia Antigen CML66 Elicits Coordinated B-Cell and T-Cell Immunity after Donor Lymphocyte Infusion

    Article • Clinical Cancer Research, May 2010, American Association for Cancer Research (AACR)

    Tetsuro Sasada

  117. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation

    Article • Proceedings of the National Academy of Sciences, September 2009, Proceedings of the National Academy of Sciences

    Tetsuro Sasada

  118. Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel

    Article • Lung Cancer, June 2009, Elsevier

    Tetsuro Sasada

  119. Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation

    Article • Cancer Chemotherapy and Pharmacology, January 2009, Springer Science + Business Media

    Tetsuro Sasada

  120. Preventive effect of a traditional herbal medicine, Hochu-ekki-to, on immunosuppression induced by surgical stress

    Article • Surgery Today, March 2008, Springer Science + Business Media

    Tetsuro Sasada

  121. Intra-arterial Infusion Chemotherapy With 5-Fluorouracil and Cisplatin in Advanced Pancreatic Cancer

    Article • American Journal of Clinical Oncology, February 2008, Wolters Kluwer Health

    Tetsuro Sasada

  122. Prognostic Significance of the Immediate Early Response Gene X-1 (IEX-1) Expression in Pancreatic Cancer

    Article • Annals of Surgical Oncology, November 2007, Springer Science + Business Media

    Dr Hiroki Hashida, Tetsuro Sasada

  123. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy

    Article • Cancer Science, September 2007, Wiley

    Tetsuro Sasada

  124. Uneventful splenectomy and cholecystectomy in a patient treated with anti-interleukin-6 receptor antibody therapy

    Article • Langenbeck s Archives of Surgery, August 2007, Springer Science + Business Media

    Tetsuro Sasada

  125. Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients

    Article • Oncology Reports, July 2007, Spandidos Publications

    Tetsuro Sasada

  126. New Peptide Vaccine Candidates for Epithelial Cancer Patients With HLA-A3 Supertype Alleles

    Article • Journal of Immunotherapy, April 2007, Wolters Kluwer Health

    Tetsuro Sasada

  127. The TCR Cβ FG Loop Regulates αβ T Cell Development

    Article • The Journal of Immunology, June 2006, Oxford University Press (OUP)

    Tetsuro Sasada

  128. Re: “The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators”

    Article • Surgery, November 2004, Elsevier

    Tetsuro Sasada

  129. Ran, a Small GTPase Gene, Encodes Cytotoxic T Lymphocyte (CTL) Epitopes Capable of Inducing HLA-A33–restricted and Tumor-Reactive CTLs in Cancer Patients

    Article • Clinical Cancer Research, October 2004, American Association for Cancer Research (AACR)

    Tetsuro Sasada

  130. Usefulness of 99mTc-Sestamibi Scintigraphy in Suggesting the Therapeutic Effect of Chemotherapy against Gastric Cancer

    Article • Clinical Cancer Research, June 2004, American Association for Cancer Research (AACR)

    Tetsuro Sasada

  131. Immediate Early Response Gene X-1, a Stress-Inducible Antiapoptotic Gene, Encodes Cytotoxic T-Lymphocyte (CTL) Epitopes Capable of Inducing Human Leukocyte Antigen-A33-Restricted and Tumor-Reactive CTLs in Gastric Cancer Patients

    Article • Cancer Research, April 2004, American Association for Cancer Research (AACR)

    Tetsuro Sasada

  132. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies

    Article • Cancer, July 2003, Wiley

    Tetsuro Sasada

  133. Change in Mitochondrial Membrane Potential in Peripheral Blood Lymphocytes, Especially in Natural Killer Cells, Is a Possible Marker for Surgical Stress on the Immune System

    Article • World Journal of Surgery, May 2003, Wiley

    Tetsuro Sasada

  134. Disparate peptide‐dependent thymic selection outcomes in β2M‐deficient mice versus TAP‐1‐deficient mice: implications for repertoire formation

    Article • European Journal of Immunology, January 2003, Wiley

    Tetsuro Sasada

  135. Involvement of the TCR Cβ FG Loop in Thymic Selection and T Cell Function

    Article • Journal of Experimental Medicine, May 2002, Rockefeller University Press

    Tetsuro Sasada

  136. Peptide-Induced Negative Selection of Thymocytes Activates Transcription of an NF-ΚB Inhibitor

    Article • Molecular Cell, March 2002, Elsevier

    Tetsuro Sasada

  137. Baicalin induces apoptosis via mitochondrial pathway as prooxidant

    Article • Molecular Immunology, February 2002, Elsevier

    Tetsuro Sasada

  138. CD2 Facilitates Differentiation of CD4 Th Cells Without Affecting Th1/Th2 Polarization

    Article • The Journal of Immunology, February 2002, Oxford University Press (OUP)

    Tetsuro Sasada

  139. Thioredoxin-mediated redox control of human T cell lymphotropic virus type I (HTLV-I) gene expression

    Article • Molecular Immunology, February 2002, Elsevier

    Tetsuro Sasada

  140. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis -diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex

    Article • Free Radical Biology and Medicine, November 2001, Elsevier

    Elias Arner, Tetsuro Sasada

  141. A Naturally Processed Mitochondrial Self-Peptide in Complex with Thymic Mhc Molecules Functions as a Selecting Ligand for a Viral-Specific T Cell Receptor

    Article • Journal of Experimental Medicine, September 2001, Rockefeller University Press

    Tetsuro Sasada

  142. Expression of thioredoxin in bleomycin-injured airway epithelium

    Article • Life Sciences, March 2001, Elsevier

    Tetsuro Sasada

  143. A Critical Role for CD2 in Both Thymic Selection Events and Mature T Cell Function

    Article • The Journal of Immunology, February 2001, Oxford University Press (OUP)

    Tetsuro Sasada

  144. Secretion of Thioredoxin Enhances Cellular Resistance tocis-Diamminedichloroplatinum (II)

    Article • Antioxidants & Redox Signaling, December 2000, Mary Ann Liebert Inc

    Tetsuro Sasada

  145. Thymic selection is influenced by subtle structural variation involving the p4 residue of an MHC class I-bound peptide

    Article • European Journal of Immunology, May 2000, Wiley

    Tetsuro Sasada

  146. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II)

    Article • Free Radical Biology and Medicine, September 1999, Elsevier

    Tetsuro Sasada

  147. Redox Control of Epstein-Barr Virus Replication by Human Thioredoxin/ATL-Derived Factor: Differential Regulation of Lytic and Latent Infection

    Article • Antioxidants & Redox Signaling, June 1999, Mary Ann Liebert Inc

    Tetsuro Sasada

  148. Transactivation of an inducible anti-oxidative stress protein, human thioredoxin by HTLV-I Tax

    Article • Immunology Letters, December 1996, Elsevier

    Tetsuro Sasada

  149. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity.

    Article • Journal of Clinical Investigation, May 1996, American Society for Clinical Investigation

    Tetsuro Sasada

  150. Thioredoxin/Adult T-Cell Leukemia-Derived Factor(ADF) and Redox Regulation.

    Article • The Journal of Toxicological Sciences, January 1996, Japanese Society of Toxicology

    Tetsuro Sasada

  151. Recurrent splenic artery aneurysms developing after aneurysmectomy without splenectomy: Report of a case

    Article • Surgery Today, February 1995, Springer Science + Business Media

    Tetsuro Sasada

  152. A Case of Focal Fatty Replacement of the Pancreas.

    Article • The Japanese Journal of Gastroenterological Surgery, January 1992, The Japanese Journal of Gastroenterological Surgery

    Tetsuro Sasada